Searchable abstracts of presentations at key conferences on calcified tissues

ba0002is9 | (1) (1) | ICCBH2013

DXA and vertebral fracture assessment

Adams Judith

Vertebral fractures (VF) in adults are the most common osteoporotic fracture, are powerful predictors of future fracture risk (hip X2; spine X5) and their prevalence increases as bone mineral density (BMD) declines. The most common imaging method for diagnosis is spinal radiography, but they can be identified fortuitously also on other imaging techniques performed for various clinical indications.1 Midline reformations of multi-detector CT (MDCT) scans of thorax and...

ba0001oc3.3 | Osteoporosis pathophysiology and genetics | ECTS2013

Distinct relationships of intramuscular and subcutaneous fat with cortical bone: findings from a cross sectional study of young adult males and females

Deere Kevin , Sayers Adrian , Viljakainen Heli , Lawlor Debbie , Sattar Naveed , Kemp John , Fraser William , Tobias Jon

Introduction: Intracellular fat within muscle and visceral tissue has been suggested to adversely influence bone development.Design: We aimed to compare associations between intramuscular and subcutaneous fat and cortical bone outcomes in young adults, in cross-sectional analyses based on the Avon Longitudinal Study of Parents and Children.Method: Data were collected from a research clinic conducted at 17 years of age. Intramuscula...

ba0001pp383 | Osteoporosis: pathophysiology and epidemiology | ECTS2013

Detection of autoantibodies to osteoprotegerin in patients with rheumatoid arthritis and their association with disease activity

Hauser Barbara , Riches Philip , Gilchrist Tamara , Wilson Jim F , Fraser William D , Ralston Stuart H

Introduction: Osteoporosis and fragility fractures are recognized complications of rheumatoid arthritis (RA). Previously Riches et al. described a patient with celiac disease and severe osteoporosis in whom neutralizing antibodies to osteoprotegerin (OPG) were present. The aim of this study was to determine if OPG autoantibodies were present in patients with RA and other rheumatic diseases and to relate these to clinical features.Methods: We dev...

ba0003pp145 | Cell biology: osteoblasts and bone formation | ECTS2014

Effects of strontium ranelate on the bone-like mineralized matrix produced in osteoblast cell cultures

Querido William , Campos Andrea , Ferreira Erlon Martins , Gil Rosane San , Rossi Alexandre , Farina Marcos

Strontium ranelate is a promising drug used in the treatment of osteoporosis. This drug has a unique dual effect on bone turnover, simultaneously increasing bone formation by osteoblasts (anabolic effect) and decreasing bone resorption by osteoclasts (antiresorptive effect). The goal of this study was to evaluate: i) anabolic effects of strontium ranelate on the formation of bone-like mineralized matrix in osteoblast cell cultures and ii) changes the drug could cause on the ma...

ba0004p106 | (1) | ICCBH2015

Metatropic dysplasia is associated with increased fracture risk and increased markers of bone turnover

Bober Michael , Duker Angela , Carney Megan , Ditro Colleen , Rogers Kenneth , Mackenzie William

Metatropic dysplasia (MD) was first described by Maroteaux et al. in 1966. Its name was derived from the Greek word metatropos which means ‘changing pattern’ because individuals with this diagnosis begin life with a short-limbed dysplasia and a long trunk with narrow chest, and over time their dysplasia becomes short-trunked due to progressive kyphoscoliosis1. It is now recognized that MD is caused by gain-of-function mutations in transie...

ba0004p176 | (1) | ICCBH2015

Evaluation of fibroblast growth factor 23 in patients with hypophosphataemic rickets

Park Julie , Khan Kursheed , Hatchard Lynne , Ramakrishnan Renuka , Senniappan Senthil , Fraser William , Dharmaraj Poonam

Objective: Hypophosphataemic rickets (HPR) is associated with high concentrations of fibroblast growth factor 23 (FGF23). Chronically elevated FGF23 may impact on cardiac function and the skeleton. There is little evidence on how FGF23 changes with time in HPR or how it is affected by treatment. The aim of this study was to evaluate changes in FGF23 concentrations over time in patients with HPR.Methods: Retrospective data was collected from our Metabolic...

ba0005p469 | Other diseases of bone and mineral metabolism | ECTS2016

FGF23 and vitamin D metabolism in chronic kidney disease – mineral bone disorder

Piec Isabelle , Chipchase Allison , Nicholls Holly , Washbourne Christopher , Tang Jonathan , Fraser William D.

Fibroblast growth factor-23 (FGF23) is a major regulator of phosphate metabolism often elevated in genetic hypophosphataemic disorders and in chronic kidney disease–bone mineral disorder (CKD–BMD). Recent studies have identified relationships between FGF23 and vitamin D.Objectives: To determine the relationship between vitamin D and FGF23 metabolism in CKD.Method: We used randomized samples from patient...

ba0006oc23 | (1) | ICCBH2017

Sustained radiographic and functional improvements with asfotase alfa treatment from up to 7 years in children with hypophosphatasia

Whyte Michael P. , Rockman-Greenberg Cheryl , Moseley Scott , Denker Andrew E. , McAlister William H.

Objective: Children with hypophosphatasia (HPP) treated with asfotase alfa in a Phase 2 study (NCT00952484) and its open-label extension (NCT01203826) experienced significant improvements in skeletal mineralization and physical function that were sustained through 5 years of treatment (1). Herein, we report data from these studies with a maximum of 7 years of treatment.Methods: Children with HPP aged 6–12 years at baseline received asfotase alfa (3 ...

ba0007p148 | (1) | ICCBH2019

Management of foramen magnum stenosis in patients with achondroplasia: relative merit of clinical and radiological indications for foramen magnum decompression

Almeida Timoteo , Singleton William , Monsell Fergal , Smithson Sarah , Edwards Richard , Burren Christine

Introduction: Achondroplasia, the commonest skeletal dysplasia, is caused by specific variant(s) in the fibroblast growth factor receptor 3 (FGFR3) gene that cause abnormal spine, skull and limb bone growth. Surgical indications for foramen magnum stenosis in this population vary widely in the literature.Methods: We performed a retrospective analysis of patients with achondroplasia aged >20 years (n=33) in our regional skeletal dysplasia cli...